Women’s preferences and acceptance for different drug delivery routes and products

To use or not to use, that is the first decision to take regarding a drug product. This mandatory step for adherence dictates product efficacy. The determinants for such decision do not only rely on the priority of the therapeutic or preventive strategy, but are related to a complex network of perceptions, preferences, personal and cultural backgrounds, and results from previous experiences. Women’s preferences for dosage forms and even for drug delivery routes have been mainly studied in the fields of contraception and HIV prevention (and their related multipurpose approaches). Much less attention has been devoted to other therapeutic or preventive strategies. In a time when patient-centred approaches and shared decisions are increasingly valued, considering women’s preferences and their main determinants is essential for product development and selection. Such products will be more likely to be chosen and used as intended, increasing efficacy, and reducing the overall costs related with these treatments. This knowledge shall be integrated in early stages of product development. This article reviews the state of the art related with women’s preferences and acceptance for different dosage forms and drug delivery routes involved in women’s health. The methodologies used for collecting these data and their major drawbacks are discussed. Results obtained from acceptability studies and the main determinants for selection of preventive and treatment drug products are discussed as tools for new developments in the field.

See the article

Rita Palmeira-de-Oliveira, Ana Sofia Oliveira, Joana Rolo, Mariana Tomás, Ana Palmeira-de-Oliveira, Sérgio Simões, José Martinez-de-Oliveira,
Women’s preferences and acceptance for different drug delivery routes and products,
Advanced Drug Delivery Reviews, Volume 182, 2022, 114133, ISSN 0169-409X,
https://doi.org/10.1016/j.addr.2022.114133.